Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Nilotinib.

Martin Gresse1, Theo D Kim2, Philipp le Coutre2

  • 1Division of Hematology and Oncology, Medical Department, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany. martin.gresse@charite.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026
Same author

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Leukemia·2026
Same author

Correction: Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97).

Frontiers in oncology·2026
Same author

Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97).

Frontiers in oncology·2026
Same author

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Leukemia·2026
Same author

Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.

Leukemia·2025
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Second-generation tyrosine kinase inhibitors (TKIs) like nilotinib offer higher response rates for chronic myeloid leukemia (CML). Stopping nilotinib treatment appears safe, maintaining remission in approximately half of eligible patients, though long-term data are pending.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Imatinib revolutionized chronic myeloid leukemia (CML) therapy, but second-generation tyrosine kinase inhibitors (TKIs) are increasingly important.
  • Nilotinib demonstrates higher response rates and comparable safety to imatinib, making it a preferred first-line option for CML.
  • Achieving deep molecular remissions with TKIs has shifted focus towards treatment discontinuation strategies.

Purpose of the Study:

  • To evaluate the safety and efficacy of nilotinib discontinuation in patients with chronic-phase CML.
  • To assess the rate of sustained molecular remission after stopping nilotinib therapy.

Main Methods:

  • Review of clinical data on patients with CML treated with nilotinib.
  • Analysis of remission status following nilotinib discontinuation.
Keywords:
CMLNilotinibTKI

Related Experiment Videos

Last Updated: Feb 7, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Main Results:

  • Nilotinib discontinuation was found to be safe in eligible CML patients.
  • Approximately 50% of patients maintained stable molecular remission after stopping nilotinib.

Conclusions:

  • Nilotinib discontinuation is a viable strategy for select CML patients.
  • Further long-term studies are necessary to fully understand the implications of stopping nilotinib.